These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Postoperative radio- and/or chemotherapy in ovarian stage III cancers. Results of a prospective randomized study].
    Author: Richter P, Sarembe B, Lotze W.
    Journal: Zentralbl Gynakol; 1985; 107(4):237-44. PubMed ID: 3885634.
    Abstract:
    In advanced ovarian carcinoma operation alone does not give any change of permanent cure. Therefore an additional treatment is necessary. From 1977 to 1980 we performed a prospective random study about the significance of postoperative radio- and chemotherapy (group A, n = 20) versus combined longterm chemotherapy (group B, n = 24) in ovarian carcinoma stage III. Radical operation was possible in 82% of all cases. 8 of them (18%) occasionally a second-look operation (A = 2, B = 6). Radiotherapy was a whole abdomen irradiation (Co60-teletherapy-40 Gy in two series, pelvis additional 20 Gy) by means of open field technique. Cyclophosphamide, methotrexate, 5-fluorouracile and vinblastine were used for the purpose of chemotherapy. The survival time was not significantly prolonged in group B (20,4 months) compared to group A (13,9 months). 44% (B) survived three years contrary to 36% (A); after four and five years survival rates are equal in both groups (A = 36%, B = 37%). Thus additional radiotherapy does not improve survival rate. On the other hand there are considerable side-effects and tolerance against chemotherapy is diminished. That is why a general radiotherapy is not recommendable in the present modification.
    [Abstract] [Full Text] [Related] [New Search]